Abstract
Nowadays, a large number of people in the world are suffering from chronic Hepatitis C. HCV NS5B polymerase conserved across the identified 7 HCV genotypes is considered to be the most promising target in combating HCV. During the past decade, significant progress has been made in the discovery of novel nucleoside HCV NS5B polymerase inhibitors. A potent anti-HCV drug, sofosbuvir with high cure rates has been approved. Besides, quite a few nucleoside anti-HCV agents are being evaluated in clinical trials. The purpose of this review is to present recent progress in the development of nucleoside HCV NS5B polymerase inhibitors, focusing on lead compounds that hold great promise for medicinal use and their structure-activity relationships (SARs) in order to provide guidance for future drug design and discovery.
Keywords: Hepatitis C virus, inhibitor, nucleoside, NS5B polymerase, prodrug, SAR.
Current Drug Targets
Title:Nucleoside Inhibitors of Hepatitis C Virus NS5B Polymerase: A Systematic Review
Volume: 17 Issue: 13
Author(s): Yuanchao Xie, Comfort Alicha Ogah, Xiangrui Jiang, Jianfeng Li and Jingshan Shen
Affiliation:
Keywords: Hepatitis C virus, inhibitor, nucleoside, NS5B polymerase, prodrug, SAR.
Abstract: Nowadays, a large number of people in the world are suffering from chronic Hepatitis C. HCV NS5B polymerase conserved across the identified 7 HCV genotypes is considered to be the most promising target in combating HCV. During the past decade, significant progress has been made in the discovery of novel nucleoside HCV NS5B polymerase inhibitors. A potent anti-HCV drug, sofosbuvir with high cure rates has been approved. Besides, quite a few nucleoside anti-HCV agents are being evaluated in clinical trials. The purpose of this review is to present recent progress in the development of nucleoside HCV NS5B polymerase inhibitors, focusing on lead compounds that hold great promise for medicinal use and their structure-activity relationships (SARs) in order to provide guidance for future drug design and discovery.
Export Options
About this article
Cite this article as:
Xie Yuanchao, Ogah Alicha Comfort, Jiang Xiangrui, Li Jianfeng and Shen Jingshan, Nucleoside Inhibitors of Hepatitis C Virus NS5B Polymerase: A Systematic Review, Current Drug Targets 2016; 17 (13) . https://dx.doi.org/10.2174/1389450117666151209123751
DOI https://dx.doi.org/10.2174/1389450117666151209123751 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Purine Nucleoside Analogues for Hematological Malignancies
Recent Patents on Anti-Cancer Drug Discovery OX40 and OX40L Interaction in Cancer
Current Medicinal Chemistry Differentiation Potential of Human Retinoblastoma Cells
Current Pharmaceutical Biotechnology The Role of SHP-2 in Cell Signalling and Human Disease
Current Enzyme Inhibition α<sub>IIb</sub>β<sub>3</sub>-integrin Ligands: Abciximab and Eptifibatide as Proapoptotic Factors in MCF-7 Human Breast Cancer Cells
Current Drug Targets A Novel H.264-Supported Approach for Detecting and Classifying Hepatic Lesions in Computed Tomographic Images
Current Medical Imaging Anticancer Alkylphospholipids: Mechanisms of Action, Cellular Sensitivity and Resistance, and Clinical Prospects
Current Pharmaceutical Design Is Going for Cure in CML Targeting Aberrant Glycogen Synthase Kinase 3β?
Current Drug Targets Polymers Based on Phenyl Boric Acid in Tumor-Targeted Therapy
Anti-Cancer Agents in Medicinal Chemistry Liposomal-All-trans-Retinoic Acid in the Treatment of Acute Promyelocytic Leukemia
Current Cancer Therapy Reviews ADAM Metalloproteinases as Potential Drug Targets
Current Medicinal Chemistry Chalcones in Cancer: Understanding their Role in Terms of QSAR. II Part
Mini-Reviews in Medicinal Chemistry High-level Soluble Expression, Purification, and Functional Characterization of the Recombinant Human Leukemia Inhibitory Factor: A Potential General Strategy for the Recombinant Expression of Cytokines Consisting of Four α-Helices in a Bundle
Protein & Peptide Letters On the Involvement of H2S in Nitroso Signaling and Other Mechanisms of H2S Action
Current Pharmaceutical Biotechnology Antibody Fragments as Potential Biopharmaceuticals for Cancer Therapy: Success and Limitations
Current Medicinal Chemistry Preparation and Surface Modification of Polymeric Nanoparticles for Drug Delivery: State of the Art
Recent Patents on Drug Delivery & Formulation Recent Patents on Live Bacteria and their Products as Potential Anticancer Agents
Recent Patents on Anti-Cancer Drug Discovery The Changing Face of HDAC Inhibitor Depsipeptide
Current Cancer Drug Targets Insects Antiviral and Anticancer Peptides: New Leads for the Future?
Protein & Peptide Letters Nucleoside Transport as a Potential Target for Chemotherapy in Malaria
Current Pharmaceutical Design